Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
On March 5, 2025, Thermo Fisher Scientific Inc. demonstrates strategic acquisitions, robust financial performance, and steady intraday momentum.
Thermo Fisher Scientific is strategically expanding through acquisitions and clinical registries, positioning itself for continued growth. Read our analysis.
Thermo Fisher Scientific (TMO) is expanding through strategic acquisitions, innovation, and shareholder value initiatives, positioning it for future growth.
Thermo Fisher Scientific expands capabilities via strategic acquisitions, innovation, and increased shareholder value. A deep dive into recent developments and market impacts.
Thermo Fisher Scientific expands bioproduction with Solventum acquisition, CEO presents at TD Cowen, and capitalizes on molecular diagnostics growth trends.
Thermo Fisher Scientific is navigating growth through strategic initiatives and market expansion, signaling a strong outlook for 2025 and beyond.
A dividend hike, board appointment, and product launches signal robust growth for Thermo Fisher Scientific.
Intraday update for Tuesday, February 18, 2025 on Thermo Fisher Scientific, highlighting new product launches, market growth forecasts and competitive insights.
This in-depth analysis details Thermo Fisher Scientific’s strong Q4 2024 results, product innovations, and strategic market expansion across key sectors.